Vanguard Group Inc. lifted its position in shares of CryoLife, Inc. (NYSE:CRY) by 6.6% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,658,646 shares of the medical equipment provider’s stock after purchasing an additional 102,540 shares during the period. Vanguard Group Inc. owned about 4.96% of CryoLife worth $33,090,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Dimensional Fund Advisors LP lifted its position in shares of CryoLife by 5.7% during the first quarter. Dimensional Fund Advisors LP now owns 1,849,248 shares of the medical equipment provider’s stock worth $30,790,000 after purchasing an additional 100,125 shares in the last quarter. Northern Trust Corp lifted its position in shares of CryoLife by 7.4% during the second quarter. Northern Trust Corp now owns 1,171,769 shares of the medical equipment provider’s stock worth $23,377,000 after purchasing an additional 81,090 shares in the last quarter. Renaissance Technologies LLC lifted its position in shares of CryoLife by 4.0% during the first quarter. Renaissance Technologies LLC now owns 547,900 shares of the medical equipment provider’s stock worth $9,123,000 after purchasing an additional 20,900 shares in the last quarter. Elk Creek Partners LLC lifted its position in shares of CryoLife by 6.1% during the second quarter. Elk Creek Partners LLC now owns 527,328 shares of the medical equipment provider’s stock worth $10,520,000 after purchasing an additional 30,411 shares in the last quarter. Finally, Royce & Associates LP lifted its position in shares of CryoLife by 10.0% during the second quarter. Royce & Associates LP now owns 435,200 shares of the medical equipment provider’s stock worth $8,682,000 after purchasing an additional 39,500 shares in the last quarter. 68.94% of the stock is currently owned by institutional investors and hedge funds.

In other CryoLife news, Director James Benson sold 2,000 shares of the business’s stock in a transaction on Monday, October 2nd. The shares were sold at an average price of $22.80, for a total transaction of $45,600.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO James P. Mackin sold 43,050 shares of the business’s stock in a transaction on Tuesday, September 5th. The shares were sold at an average price of $22.09, for a total transaction of $950,974.50. Following the sale, the chief executive officer now owns 398,399 shares of the company’s stock, valued at approximately $8,800,633.91. The disclosure for this sale can be found here. In the last quarter, insiders have sold 172,050 shares of company stock valued at $3,788,855. 6.00% of the stock is owned by insiders.

A number of brokerages recently issued reports on CRY. BidaskClub lowered shares of CryoLife from a “buy” rating to a “hold” rating in a research note on Monday, July 24th. Zacks Investment Research upgraded shares of CryoLife from a “sell” rating to a “hold” rating in a research note on Monday, August 14th. Lake Street Capital lifted their price target on shares of CryoLife to $26.00 and gave the stock a “buy” rating in a research note on Wednesday, October 11th. TheStreet lowered shares of CryoLife from a “b” rating to a “c+” rating in a research note on Monday, October 30th. Finally, Canaccord Genuity restated a “buy” rating and issued a $25.00 price target on shares of CryoLife in a research note on Monday, October 9th. Two research analysts have rated the stock with a sell rating and four have given a buy rating to the stock. The company has an average rating of “Hold” and an average price target of $23.63.

Shares of CryoLife, Inc. (CRY) opened at $18.85 on Friday. The company has a quick ratio of 4.90, a current ratio of 5.96 and a debt-to-equity ratio of 0.29. The stock has a market cap of $635.69, a price-to-earnings ratio of 46.34 and a beta of 0.82. CryoLife, Inc. has a 12 month low of $14.02 and a 12 month high of $24.00.

CryoLife (NYSE:CRY) last issued its quarterly earnings results on Monday, October 30th. The medical equipment provider reported $0.08 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.08. The business had revenue of $44.00 million during the quarter, compared to analyst estimates of $44.60 million. CryoLife had a net margin of 5.28% and a return on equity of 6.43%. The business’s revenue was down 2.9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.13 earnings per share. analysts expect that CryoLife, Inc. will post 0.28 EPS for the current year.

ILLEGAL ACTIVITY WARNING: “Vanguard Group Inc. Purchases 102,540 Shares of CryoLife, Inc. (CRY)” was reported by Daily Political and is the property of of Daily Political. If you are reading this story on another website, it was illegally copied and reposted in violation of international trademark and copyright laws. The correct version of this story can be viewed at https://www.dailypolitical.com/2017/11/10/vanguard-group-inc-purchases-102540-shares-of-cryolife-inc-cry.html.

About CryoLife

CryoLife, Inc (CryoLife) is a medical device manufacturer and processor, and is engaged in the distribution of medical devices and implantable human tissues used in cardiac surgical procedures. The Company operates through two segments: Medical Devices and Preservation Services. The Medical Devices segment includes medical devices, such as BioGlue Surgical Adhesive, BioFoam Surgical Matrix, On-X Life Technologies Holdings, Inc valves and surgical products, CardioGenesis cardiac laser therapy product line, PerClot and PhotoFix.

Institutional Ownership by Quarter for CryoLife (NYSE:CRY)

Receive News & Ratings for CryoLife Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CryoLife Inc. and related companies with MarketBeat.com's FREE daily email newsletter.